Ovarian Cancer | Specialty

PARP Inhibitor Side Effect Management in Ovarian Cancer

December 23rd 2017

Ovarian Cancer: Deciding Among PARP Inhibitors

December 23rd 2017

Ovarian Cancer Decisions: Treatment Versus Maintenance

December 23rd 2017

Talking With Patients About Recurrence Risk in Ovarian Cancer

December 23rd 2017

Ovarian Cancer: Making Treatment Plans Together

December 23rd 2017

Options With Genetic Testing in Ovarian Cancer

December 23rd 2017

Platinum Sensitivity and PARP Inhibition in Ovarian Cancer

December 23rd 2017

Ovarian Cancer: Talking to Patients About PARP Inhibitors

December 23rd 2017

Future of Immunotherapy in Ovarian Cancer to Include Combinations

December 22nd 2017

Bradley J. Monk, MD, discusses pivotal trials, as well as the potential for immunotherapy in ovarian cancer.

Dr. Markman on the Era of Precision Medicine in Ovarian Cancer

December 19th 2017

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses the era of precision medicine in ovarian cancer.

Dr. Levine on Sequencing of Agents for Ovarian Cancer

December 14th 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the sequencing of agents for patients with ovarian cancer.

Dr. Monk Discusses Immunotherapy in Ovarian Cancer

December 12th 2017

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for the treatment of patients with ovarian cancer.

FDA Grants Priority Review to Maintenance Rucaparib for Ovarian Cancer

December 6th 2017

The FDA has granted a priority review to a supplemental new drug application for rucaparib (Rubraca) for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Time Between Neoadjuvant and Adjuvant Chemo Impacts OS in Ovarian Cancer

December 5th 2017

Patients with ovarian cancer who begin postoperative adjuvant chemotherapy within 42 days of ending neoadjuvant chemotherapy have superior survival compared to those who initiate therapy after that point.

Dr. Sabbatini on Novel Approaches With IP Therapy For Ovarian Cancer

November 30th 2017

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.

Dr. Dottino on Targeted Therapies in Ovarian Cancer

November 28th 2017

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses targeted therapies for patients with ovarian cancer.

Niraparib Approved in Europe for Ovarian Cancer

November 23rd 2017

The European Commission has approved niraparib as a maintenance therapy for women with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Expert Discusses Promise of Checkpoint Inhibitors in Ovarian Cancer

November 21st 2017

Jonathan Ledermann, MD, discusses the promise of immunotherapy in ovarian cancer and emphasized the importance of participation in clinical trials.

Dr. Leitao on the Benefits of Surgery in Ovarian Cancer

November 21st 2017

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the importance of surgery for patients with ovarian cancer.

The Future Role of PARP Inhibition in Ovarian Cancer

November 20th 2017